Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.

Reimbursement Market Access Neurology
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

GIST Market Comes Of Age

Patent expiries, novel pipeline treatments, and more patients are set to shake up the gastrointestinal stromal tumor market, finds Datamonitor Healthcare.

Market Intelligence Research & Development

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

Market Intelligence ImmunoOncology

CNS Refresh: Boehringer's New Approach To Tricky Neuropsychiatry Diseases

Boehringer Ingelheim is seeking partners with early-stage, novel approaches to neuropsychiatry disorders under its strategy of applying "fresh thinking" to diseases of the central nervous system with high unmet need.

Neurology Business Strategies

Five Themes For BIO-Europe 2017

From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.

Brexit Business Strategies

CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients

Data for JCAR017 in diffuse large B-cell lymphoma to be presented at the upcoming ASH meeting suggest that the therapy has best-in-class safety and efficacy, paving the way for use outside major medical centers, a potential competitive advantage.

ImmunoOncology Cancer

Life In The Old Dog Yet: Growth In Dyslipidemia Market Expected To 2025

Despite the further genericization of statins and ezetimibe, the arrival of expensive new therapies means the dyslipidemia market is still set for growth over the next eight years, say analysts from Datamonitor Healthcare.

Commercial Market Intelligence
See All
UsernamePublicRestriction

Register